Cite
HARVARD Citation
Sugimoto, D. et al. (2018). Efficacy of iGlarLixi, a fixed‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements. Diabetes, obesity & metabolism. 20 (11), pp. 2680-2684. [Online].